Induced pluripotent stem cell–based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients

INTRODUCTION: Amyotrophic lateral sclerosis (ALS) is a progressive and severe neurodegenerative disease caused by motor neuron death. There have as yet been no fundamental curative medicines, and the development of a medicine for ALS is urgently required. Induced pluripotent stem cell (iPSC)-based d...

Descripción completa

Detalles Bibliográficos
Autores principales: Imamura, Keiko, Izumi, Yuishin, Banno, Haruhiko, Uozumi, Ryuji, Morita, Satoshi, Egawa, Naohiro, Ayaki, Takashi, Nagai, Makiko, Nishiyama, Kazutoshi, Watanabe, Yasuhiro, Hanajima, Ritsuko, Oki, Ryosuke, Fujita, Koji, Takahashi, Naoto, Ikeda, Takafumi, Shimizu, Akira, Morinaga, Akiko, Hirohashi, Tomoko, Fujii, Yosuke, Takahashi, Ryosuke, Inoue, Haruhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003406/
https://www.ncbi.nlm.nih.gov/pubmed/31796494
http://dx.doi.org/10.1136/bmjopen-2019-033131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003406/
https://www.ncbi.nlm.nih.gov/pubmed/31796494
http://dx.doi.org/10.1136/bmjopen-2019-033131

Ejemplares similares